Skip to content

Studying blood markers in sepsis patients to improve diagnosis and treatment

Exploring the Differential Immune Responses in Community-Acquired Sepsis through Plasma Mediators and Immune Cell Analysis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/094788
Enrollment
120
Registered
2025-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A419- Sepsis, unspecified organism

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Manipal Academy of Higher Education, Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient Group 1. Adult patients (age 18 and above) admitted to the ICUs with sepsis, shock and other inflammatory conditions like trauma, poisoning, pancreatitis. 2. SOFA score greater than 2 Healthy Controls 1. Healthy adults (18 years and above) not admitted to the hospital or those with well-controlled underlying conditions (hypertension, diabetes etc.) 2. Able and willing to provide the informed consent.

Exclusion criteria

Exclusion criteria: Patient group 1. Age less than 18 years 2. Pregnant or breast-feeding women 3. Confirmed viral, fungal, parasitic, polymicrobial infections. 4. Patients with a withdrawal of care decision at time of inclusion 5. Patients whose anticipated duration of hospitalisation in ICU is estimated less than 48 hours. 6. Patient with restricted liberty or under legal protection 7. Expected lifespan less than 3 months due to pre-existing co-morbidities 8. Blood transfusion greater than 4 units in past week 9. Second admission to ICU or previous enrolment in study (within same hospital admission) Transfer from other hospital ICU Healthy Controls 1. Age less than 18 years 2. Pregnant or breast-feeding 2. Infected with any infectious diseases 3. Hemophilia, severe coagulation disorders or impaired venous access 4. Prolonged antibiotic usage in the last 3 months 5. History of sepsis/septic shock in the last 6 months

Design outcomes

Primary

MeasureTime frame
Association of plasma and immune cell mediators with 28 day mortalityTimepoint: Three time points from ICU admission to 28 day follow up

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactAnusree A

Kasturba Medical College, Manipal

anusree.kmcmpl2024@learner.manipal.edu9947713619

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026